Benefits and harms of Pregabalin in the management of neuropathic pain
A meta-analysis of phase III, randomised, placebo-controlled trials has assessed the benefits and harms of Pregabalin ( Lyrica ) in the management of neuropathic pain in adults aged 18 years and above.
The neuropathic pain was defined according to the International Association for the Study of Pain ( IASP ) criteria.
The primary outcomes were pain ( as measured using validated scales ) and adverse events.
The secondary outcomes were sleep disturbance, quality of life, Patient Global Impression of Change, Clinician Global Impression scale, anxiety and depression scores, overall discontinuations and discontinuations because of adverse events.
28 trials comprising 6087 participants were included.
The neuropathic pain conditions studied were diabetic peripheral neuropathy, postherpetic neuralgia, herpes zoster, sciatica ( radicular pain ), poststroke pain and spinal cord injury-related pain.
Patients who took Pregabalin reported significant reductions in pain ( numerical rating scale [ NRS ] ) compared with placebo ( standardised mean difference [ SMD ] -0.49 [ 95% CI -0.66 to -0.32, p less than 0.00001 ], very low quality evidence ).
Pregabalin significantly reduced sleep interference scores ( NRS ) compared with placebo ( SMD -0.38 [ 95% CI -0.50 to -0.26, p less than 0.00001 ], moderate quality evidence.
Pregabalin significantly increased the risk of adverse events compared with placebo ( RR 1.33 [ 95% CI 1.23 to 1.44, p less than 0.00001, low quality evidence ] ).
The risks of experiencing weight gain, somnolence, dizziness, peripheral oedema, fatigue, visual disturbances, ataxia, non-peripheral oedema, vertigo and euphoria were significantly increased with Pregabalin.
Pregabalin was significantly more likely than placebo to lead to discontinuation of the drug because of adverse events ( RR 1.91 [ 95% CI 1.54 to 2.37, p less than 0.00001 ], low quality evidence ).
In conclusion, Pregabalin has beneficial effects on some symptoms of neuropathic pain. However, its use significantly increases the risk of a number of adverse events and discontinuation due to adverse events.
The quality of the evidence from journal publications was low. ( Xagena )
Onakpoya IJ et al, BMJ Open 2019;9(1):e023600. doi: 10.1136/bmjopen-2018-023600.
Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge
The medium-term effects of Coronavirus disease ( COVID-19 ) on multiple organ health, exercise capacity, cognition, quality of life and...
Post-Finasteride syndrome in patients during and/or after discontinuing Finasteride treatment in men with pattern hair loss or benign prostatic hyperplasia
Post-Finasteride syndrome ( PFS ) is a constellation of serious adverse side effects manifested in clinical symptoms that develop and...
EMA ( European Medicines Agency ) has granted conditional marketing authorisation for the vaccine Comirnaty, developed by BioNTech and Pfizer,...
Rozlytrek for patients whose cancers NTRK gene fusion and for patients with ROS1-positive non-small cell lung cancer, FDA approved
The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Rozlytrek ( Entrectinib ), a treatment...
Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, FDA approved
The FDA ( U.S. Food and Drug Administration ) has approved Sunosi ( Solriamfetol ) to improve wakefulness in adult...
The FDA ( U.S. Food and Drug Administration ) has approved Spravato ( Esketamine ) nasal spray, in conjunction with...
Waylivra ( Volanesorsen ) has received conditional marketing authorization from the European Commission ( EC ) as an adjunct to...
The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...
The FDA ( U.S. Food and Drug Administration ) has approved Siliq ( Brodalumab ) to treat adults with moderate-to-severe...